| abstract |
Disclosed are a humanized monoclonal antibody against PcrV or a part thereof and a pharmaceutical composition comprising the humanized monoclonal antibody or a part thereof as an active ingredient, both of which are effective means for the treatment of infectious diseases, particularly infectious diseases induced by Pseudomonas aeruginosa . Specifically, the humanized monoclonal antibody has an excellent inhibitory activity on the cytotoxicity of Pseudomonas aeruginosa against a target cell. The humanized monoclonal antibody has a high affinity for PcrV. |